ETF Managers Group, LLC Chimerix Inc Transaction History

ETF Managers Group, LLC

$2.78 Billion
Q1 2023

A detailed history of ETF Managers Group, LLC transactions in Chimerix Inc stock. As of the latest transaction made, ETF Managers Group, LLC holds 29,405 shares of CMRX stock, worth $251,118. This represents 0.0% of its overall portfolio holdings.

Number of Shares

29,405

Previous 21,951 33.96%

Holding current value

$251,118

Previous $40,000 7.5%

% of portfolio

0.0%

Previous 0.0%

12 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q1 2023 Apr 17, 2023	BUY	$1.19 - $2.09 $8,870 - $15,578	7,454 Added 33.96%	29,405 $37,000
Q4 2022 Mar 23, 2023	SELL	$1.67 - $2.35 $6,523 - $9,179	-3,906 Reduced 15.11%	21,951 $40,000
Q3 2022 Nov 14, 2022	SELL	$1.81 - $2.76 $3,198 - $4,876	-1,767 Reduced 6.4%	25,857 $50,000
Q2 2022 Aug 15, 2022	BUY	$1.34 - $5.34 $1,642 - $6,546	1,226 Added 4.64%	27,624 $57,000
Q1 2022 May 13, 2022	BUY	$4.58 - $6.8 $650 - $965	142 Added 0.54%	26,398 $122,000
Q4 2021 Feb 14, 2022	SELL	$5.23 - $7.18 $22,970 - $31,534	-4,392 Reduced 14.33%	26,256 $174,000
Q3 2021 Nov 15, 2021	BUY	$5.94 - $8.75 $31,006 - $45,675	5,220 Added 20.53%	30,648 $190,000
Q2 2021 Aug 16, 2021	SELL	$7.54 - $9.79 $6,499 - $8,438	-862 Reduced 3.28%	25,428 $192,000
Q1 2021 May 17, 2021	SELL	$4.76 - $11.25 $19,873 - $46,968	-4,175 Reduced 13.7%	26,290 $226,000
Q4 2020 Feb 16, 2021	SELL	$2.43 - $5.42 $10,614 - $23,674	-4,368 Reduced 12.54%	30,465 $148,000
Q3 2020 Nov 16, 2020	BUY	$2.3 - $3.72 $38,370 - $62,060	16,683 Added 91.92%	34,833 $88,000
Q2 2020 Aug 14, 2020	BUY	$1.33 - $3.63 $24,139 - $65,884	18,150 New	18,150 $57,000

Others Institutions Holding CMRX

# of Institutions

Shares Held

1.89M

Call Options Held

Put Options Held

View Full List

About CHIMERIX INC

Ticker CMRX
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 87,622,896
Market Cap $748M
Description
Chimerix, Inc., a biopharmaceutical company, develops medicines to enhance the lives of patients living with serious diseases. The company's approved product is TEMBEXA (brincidofovir), a lipid conjugate through inhibition of viral DNA synthesis that is developed as a medical countermeasure for smallpox. Its clinical stage development programs i...

More about CMRX

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of ETF Managers Group, LLC, based on Form 13F filings with the SEC.

News

Stay updated on ETF Managers Group, LLC with notifications on news.

Account

ETF Managers Group, LLC Chimerix Inc Transaction History